EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

ATOSIBAN VS CONVENTIONAL TREATMENT FOR THREATENED PRETERM LABOUR

Slagjana Simeonova Krstevska*, Igor Samardziski, Iva Paneva, Marija Joskimovic, Vesna Velic Stefanovska, Viktorija Jovanovska, Irena Todorovska, Vesna Livrinova, Goran Kocoski, Maja Pejkovska Ilieva, Daniel Milkovski, Aneta Sima and Vlatko Girevski

ABSTRACT

Preterm birth, a birth that occurs before 37 weeks of gestation is the most importrant cause of neonatal mortality and morbidity worldwide. Aim of the study: To evaluate the efficacy of atosiban in cases of threatened preterm labour in different gestational age and compare it with the conventional treatment. Material and methods: The data of pregnant women with threatened preterm labor hospitalized in the department for peripartal intensive care were collected in a period of 2019- 2021. The study included an pregnant women between 18 and 45 years old in gestational age between 24 and 34+6 weeks that fulfilled the nececery criteria for threatened preterm contractions.Atosiban was compared to conventional treatment (indomethacin, magnesium sulphate and calcium channel blockers, alone or in combination). Data about the treatment, perinatal outcome and maternal safety information were all collected from medical record. Results: Significant difference was found in the atosiban group in means of prolongation of pregnancy compared to conventional treatment. There was significantly longer pregnancy length in atosiban treatment group compared to conventionaly treated when gestational week at admission was ≥ 28 + 0 days (p=0,034), no previous parity (p=0,013), and no history of previous preterm birth (p=0,016). In the atosiban group there was a significant moderate positive correlation between prolonged pregnancy in days and cervical length for r(40)=0,404; p=0,011. Therefore with increasement of cervical length there was a significant prolonged duration of pregnancy. Conclusion: We found that atosiban was more effective than conventional treatment in the gestational age >28 weeks.

Keywords: atosiban, conventional treatment, preterm delivery.

[Full Text Article] [Download Certificate]